| Literature DB >> 28829913 |
Marco Derudas1, Christophe Vanpouille2, Davide Carta1, Sonia Zicari2, Graciela Andrei3, Robert Snoeck3, Andrea Brancale1, Leonid Margolis2, Jan Balzarini3, Christopher McGuigan1.
Abstract
Following our findings on the anti-human immunodeficiency virus (HIV) activity of acyclovir (ACV) phosphate prodrugs, we herein report the ProTide approach applied to a series of acyclic nucleosides aimed at the identification of novel and selective antiviral, in particular anti-HIV agents. Acyclic nucleoside analogues used in this study were identified through a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and human DNA polymerase γ. A total of 39 new phosphate prodrugs were synthesized and evaluated against HIV-1 (in vitro and ex vivo human tonsillar tissue system) and human herpes viruses. Several ProTide compounds showed substantial potency against HIV-1 at low micromolar range while the parent nucleosides were not effective. Also, pronounced inhibition of herpesvirus replication was observed. A carboxypeptidase-mediated hydrolysis study was performed for a selection of compounds to assess the formation of putative metabolites and support the biological activity observed.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28829913 PMCID: PMC5731253 DOI: 10.1021/acs.jmedchem.7b01009
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446